Case number 2017-2078
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ACORDA THERAPEUTICS, INC. v. ROXANE LABORATORIES, INC. [OPINION] [precedential] (0) |
| Oct 8, 2019 | 173 | The petition for writ of certiorari, [18-1280], filed on 04/04/2019, was Denied on 10/07/2019. [640871] [JAB] [Entered: 10/08/2019 08:24 AM] (1) |
| Apr 8, 2019 | 172 | Petition for writ of Certiorari filed on 04/04/2019, and placed on the docket 04/08/2019, in the Supreme Court of the United States. Supreme Court #: 18-1280, Accord Healthcare, Inc. v. Roxane Laboratories, Inc., et al. [598768] [JAB] [Entered: 04/09/2019 02:56 PM] (1) |
| Jan 11, 2019 | 171 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [577644] [17-2078, 17-2134] [PBC] [Entered: 01/11/2019 12:27 PM] (2) |
| Jan 4, 2019 | 170 | ORDER filed denying [145] petition for en banc rehearing filed by Acorda Therapeutics, Inc. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [575847] [PBC] [Entered: 01/04/2019 09:04 AM] (2) |
| Nov 29, 2018 | 169 | 18 paper copies of the response [167] received from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [568571] [JAB] [Entered: 11/29/2018 01:32 PM] (0) |
| Nov 28, 2018 | 168 | 18 paper copies of the response [166] received from Appellee Alkermes Pharma Ireland Limited. [568311] [JAB] [Entered: 11/28/2018 04:32 PM] (0) |
| Nov 27, 2018 | 166 | CORRECTED ENTRY: RESPONSE of Appellee Alkermes Pharma Ireland Limited to the petition for en banc rehearing [145] filed by Appellant Acorda Therapeutics, Inc. in 17-2078. Service: 11/27/2018 by email. [568013]--[Edited 11/28/2018 by JAB - Reason: To correct event] [Jeremy Tigan] [Entered: 11/27/2018 06:02 PM] (19) |
| Nov 27, 2018 | 167 | RESPONSE of Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to the petition [145] filed by Appellant Acorda Therapeutics, Inc.. Service: 11/27/2018 by email. [568025] [17-2078] [Charles Klein] [Entered: 11/27/2018 07:39 PM] (22) |
| Nov 9, 2018 | 162 | **TEXT ONLY** ORDER granting motion to withdraw attorneys [154] Sarah Kagan and Lisa Hemmendinger filed by Amicus Curiae Biotechnology Innovation Organization. BIO should promptly designate new lead attorney. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [563783] [SJ] [Entered: 11/09/2018 08:35 AM] (0) |
| Nov 9, 2018 | 163 | Amended Entry of appearance for Melissa A. Brand as principal counsel for Amicus Curiae Biotechnology Innovation Organization. Service: 11/09/2018 by email. [563886] [17-2078] [Melissa Brand] [Entered: 11/09/2018 11:16 AM] (2) |
| Nov 9, 2018 | 164 | 30 paper copies of the amicus Brief [161] received from Amicus Curiae Pharmaceutical Research and Manufacturers of America. [564371] [SJ] [Entered: 11/13/2018 12:45 PM] (0) |
| Nov 8, 2018 | 158 | ORDER filed granting motion to extend time to file response to rehearing/en banc [150] filed by Cross-Appellants Teva Pharmaceuticals USA, Inc., Roxane Laboratories, Inc. and Appellee Alkermes Pharma Ireland Limited. By: (Per Curiam). Service as of this date by the Clerk of Court. [563647] [SJ] [Entered: 11/08/2018 03:56 PM] (2) |
| Nov 8, 2018 | 159 | ORDER filed granting motion leave to file amicus brief on en banc or rehearing petition [156] filed by Amicus Curiae Pharmaceutical Research and Manufacturers of America, granting motion leave to file amicus brief on en banc or rehearing petition [152] filed by Amicus Curiae Biotechnology Innovation Organization. By: (Per Curiam). Service as of this date by the Clerk of Court. [563690] [SJ] [Entered: 11/08/2018 04:49 PM] (2) |
| Nov 8, 2018 | 160 | AMICUS BRIEF FILED on Petition for Biotechnology Innovation Organization [153]. Pages: 12. The filer is directed to submit the approriate number of copies within two days, see Fed. Cir. R. 25(c). [563777] [SJ] [Entered: 11/09/2018 08:24 AM] (18) |
| Nov 8, 2018 | 161 | AMICUS BRIEF FILED on Petition for Pharmaceutical Research and Manufacturers of America [157]. Pages: 11. The filer is directed to submit the approriate number of copies within two days, see Fed. Cir. R. 25(c). [563778] [SJ] [Entered: 11/09/2018 08:26 AM] (19) |
| Nov 8, 2018 | 165 | 18 paper copies of the amicus Brief [160] received from Amicus Curiae Biotechnology Innovation Organization. [564373] [SJ] [Entered: 11/13/2018 12:47 PM] (0) |
| Nov 7, 2018 | 151 | Entry of appearance for Brian P. Barrett as of counsel for Amicus Curiae Biotechnology Innovation Organization. Service: 11/07/2018 by email. [563343] [17-2078] [Melissa Brand] [Entered: 11/07/2018 03:27 PM] (2) |
| Nov 7, 2018 | 152 | MOTION of Amicus Curiae Biotechnology Innovation Organization for leave to file amicus brief in support of Appellant on petition for en banc rehearing [145] [Consent: partial consent]. Service: 11/07/2018 by email. [563349] [17-2078] [Melissa Brand] [Entered: 11/07/2018 03:35 PM] (7) |
| Nov 7, 2018 | 153 | TENDERED from Amicus Curiae Biotechnology Innovation Organization. Title: AMICUS CURIAE BRIEF. Service: 11/07/2018 by email. [563351] [17-2078] [Melissa Brand] [Entered: 11/07/2018 03:37 PM] (18) |
| Nov 7, 2018 | 154 | MOTION of Amicus Curiae Biotechnology Innovation Organization to withdraw counsel Sarah A. Kagan and Lisa M. Hemmendinger [Consent: unopposed]. Service: 11/07/2018 by email. [563352] [17-2078] [Melissa Brand] [Entered: 11/07/2018 03:38 PM] (6) |
| Nov 7, 2018 | 155 | **TEXT ONLY** ORDER granting motion to withdraw attorney [149] Maryellen Noreika filed by Appellee Alkermes Pharma Ireland Limited. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [563391]--[Edited 11/07/2018 by SMJ to reflect EOA for lead attorney being submitted [148]] [SJ] [Entered: 11/07/2018 04:19 PM] (0) |
| Nov 7, 2018 | 156 | MOTION of Amicus Curiae Pharmaceutical Research and Manufacturers of America for leave to file amicus brief in support of Appellant Acorda on petition for en banc rehearing [145] [Consent: unopposed]. Service: 11/07/2018 by email. [563424] [17-2078] [Brianne Bharkhda] [Entered: 11/07/2018 05:06 PM] (7) |
| Nov 7, 2018 | 157 | TENDERED from Amicus Curiae Pharmaceutical Research and Manufacturers of America. Title: AMICUS CURIAE BRIEF. Service: 11/07/2018 by email. [563426] [17-2078] [Brianne Bharkhda] [Entered: 11/07/2018 05:13 PM] (19) |
| Nov 6, 2018 | 148 | Entry of appearance for Jack B. Blumenfeld as principal counsel for Appellee Alkermes Pharma Ireland Limited. Service: 11/06/2018 by email. [563128] [17-2078] [Jeremy Tigan] [Entered: 11/06/2018 10:22 PM] (1) |
| Nov 6, 2018 | 149 | MOTION of Appellee Alkermes Pharma Ireland Limited to withdraw counsel Maryellen Noreika [Consent: unopposed]. Service: 11/06/2018 by email. [563129] [17-2078] [Jeremy Tigan] [Entered: 11/06/2018 10:24 PM] (6) |
| Nov 6, 2018 | 150 | MOTION of Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to extend the time to file a response to the Combined Petition for Panel Rehearing and Rehearing En Banc until 11/27/2018 [Consent: unopposed]. Service: 11/06/2018 by email. [563130] [17-2078] [Jeremy Tigan] [Entered: 11/06/2018 10:32 PM] (9) |
| Oct 29, 2018 | 147 | The court invites a response from Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to the petition for en banc rehearing filed by Appellant in 17-2078. The responses are due on or before 11/13/2018. [560984] [JAB] [Entered: 10/29/2018 02:55 PM] (1) |
| Oct 25, 2018 | 146 | 18 paper copies of the petition for en banc rehearing [145] received from Appellant Acorda Therapeutics, Inc. [560386] [JAB] [Entered: 10/25/2018 01:37 PM] (0) |
| Oct 24, 2018 | 145 | Petition for en banc rehearing filed by Appellant Acorda Therapeutics, Inc.. Service: 10/24/2018 by email. The paper copies of the petition must be filed within two business days (see Fed. Cir. R. 35(c)(4).The required paper copies should be received by the court on or before 10/26/2018 [560224] [17-2078] [Bruce Wexler] [Entered: 10/24/2018 09:42 PM] (107) |
| Sep 19, 2018 | 144 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [143] filed by Appellant Acorda Therapeutics, Inc. Petition for Rehearing due on or before 10/24/2018. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [551010] [JAB] [Entered: 09/19/2018 12:40 PM] (2) |
| Sep 18, 2018 | 143 | MOTION of Appellant Acorda Therapeutics, Inc. to extend the time to file a Petition for Rehearing En Banc until 10/24/2018 [Consent: unopposed]. Service: 09/18/2018 by email. [550844] [17-2078] [Igor Timofeyev] [Entered: 09/18/2018 07:08 PM] (9) |
| Sep 10, 2018 | 142 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed, Cross-Appeal dismissed as moot. (Precedential Opinion). (For the Court: Newman, Circuit Judge; Dyk, Circuit Judge and Taranto, Circuit Judge). Dissenting opinion filed by Circuit Judge Newman. [548330] [17-2078, 17-2134] [SJ] [Entered: 09/10/2018 10:10 AM] (84) |
| Aug 24, 2018 | 141 | **TEXT ONLY** ORDER granting motion to withdraw attorney [140] Samuel Park filed by Cross-Appellants Teva Pharmaceuticals USA, Inc. and Roxane Laboratories, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [545204] [SJ] [Entered: 08/24/2018 10:25 AM] (0) |
| Aug 23, 2018 | 140 | MOTION of Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to withdraw counsel Samuel S. Park [Consent: unopposed]. Service: 08/23/2018 by email. [545021] [17-2078] [Charles Klein] [Entered: 08/23/2018 03:38 PM] (7) |
| Aug 22, 2018 | 139 | **TEXT ONLY** ORDER granting motion to withdraw attorney [138] Gerald J. Flattmann, Jr. filed by Appellant Acorda Therapeutics, Inc.. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [544552] [SJ] [Entered: 08/22/2018 09:21 AM] (0) |
| Aug 21, 2018 | 138 | MOTION of Appellant Acorda Therapeutics, Inc. to withdraw counsel Gerald J. Flattmann, Jr. [Consent: unopposed]. Service: 08/21/2018 by email. [544517] [17-2078] [Igor Timofeyev] [Entered: 08/21/2018 07:18 PM] (6) |
| Jul 25, 2018 | 137 | ORDER filed denying [122] motion for temporary injunction pending appeal filed by Acorda Therapeutics, Inc. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [538475] [SJ] [Entered: 07/25/2018 11:13 AM] (3) |
| Jul 23, 2018 | 136 | Letter from Appellant Acorda Therapeutics, Inc. regarding Emergency Motion for Injunction. Service: 07/23/2018 by email. [537998] [17-2078] [Wenying Chang] [Entered: 07/23/2018 07:22 PM] (2) |
| Jul 5, 2018 | 135 | Corrected Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 07/05/2018 by email. [533650] [17-2078] [Charles Klein] [Entered: 07/05/2018 09:34 AM] (3) |
| Jul 2, 2018 | 134 | Amended Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 07/02/2018 by email. [533158] [17-2078] [Charles Klein] [Entered: 07/02/2018 02:56 PM] (3) |
| Jun 14, 2018 | 132 | MOTION of Appellant Acorda Therapeutics, Inc. to withdraw counsel Alexandra H. Moss [Consent: unopposed]. Service: 06/14/2018 by email. [529348] [17-2078] [Wenying Chang] [Entered: 06/14/2018 10:57 AM] (5) |
| Jun 14, 2018 | 133 | **TEXT ONLY** ORDER granting motion to withdraw attorney [132] Alexandra Moss filed by Appellant Acorda Therapeutics, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [529367] [SJ] [Entered: 06/14/2018 11:39 AM] (0) |
| Jun 13, 2018 | 130 | Letter from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. Submission of Exhibit 1 from Joint Appendix. Service: 06/13/2018 by email. [529197] [17-2078] [Charles Klein] [Entered: 06/13/2018 04:14 PM] (4) |
| Jun 13, 2018 | 131 | RESPONSE of Appellant Acorda Therapeutics, Inc. to the party letter [130] filed by Cross-Appellants Teva Pharmaceuticals USA, Inc. and Roxane Laboratories, Inc. in 17-2078. Service: 06/13/2018 by email. [529210]--[Edited 06/14/2018 by SMJ - Reason: to correct event] [Bruce Wexler] [Entered: 06/13/2018 04:42 PM] (2) |
| Jun 12, 2018 | 129 | Letter from Appellant Acorda Therapeutics, Inc. and Cross-Appellants Roxane Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Mylan Pharmaceuticals Inc. regarding Joint Refiling of Joint Appendix Page A6501. Service: 06/12/2018 by email. [528907] [17-2078] [Bruce Wexler] [Entered: 06/12/2018 09:42 PM] (7) |
| Jun 7, 2018 | 128 | Submitted after ORAL ARGUMENT by Bruce M. Wexler for Acorda Therapeutics, Inc. and Charles B. Klein for Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc. and Roxane Laboratories, Inc. Panel: Judge: Newman , Judge: Dyk , Judge: Taranto. [527638] [JAB] [Entered: 06/07/2018 12:20 PM] (0) |
| Jun 6, 2018 | 126 | REPLY of Appellant Acorda Therapeutics, Inc. to response filed by Cross-Appellants, Doc. No [124]. Service: 06/06/2018 by email, US mail. [527436] [17-2078] [Wenying Chang] [Entered: 06/06/2018 03:58 PM] (20) |
| Jun 6, 2018 | 127 | Sealed or confidential document received [APPELLANT ACORDA THERAPEUTICS, INC.S REPLY IN SUPPORT OF ITS MOTION FOR AN INJUNCTION PENDING APPEAL] (corresponding to Doc No. [126]) for Appellant Acorda Therapeutics, Inc.. Service: 06/06/2018 by email. [527445] [17-2078] [Wenying Chang] [Entered: 06/06/2018 04:10 PM] (0) |
| May 30, 2018 | 124 | RESPONSE of Cross-Appellants Roxane Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Mylan Pharmaceuticals Inc. to the motion for temporary injunction pending appeal [122] filed by Appellant Acorda Therapeutics, Inc.. Service: 05/30/2018 by email. [525663] [17-2078] [Charles Klein] [Entered: 05/30/2018 08:40 PM] (28) |
| May 30, 2018 | 125 | Sealed or confidential document received [Opposition to Motion for an Injunction Pending Appeal] (corresponding to Doc No. [124]) for Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 05/30/2018 by email. [525664] [17-2078] [Charles Klein] [Entered: 05/30/2018 08:56 PM] (0) |
| May 23, 2018 | 122 | MOTION of Appellant Acorda Therapeutics, Inc. for temporary injunction [Consent: opposed]. Service: 05/23/2018 by email, US mail. [524068] [17-2078] [Wenying Chang] [Entered: 05/23/2018 04:48 PM] (148) |
| May 23, 2018 | 123 | Sealed or confidential document received [Appellant Acorda Therapeutics, Inc.'s Motion For An Injunction Pending Appeal with exhibits D, E, and F] (corresponding to Doc No. [122]) for Appellant Acorda Therapeutics, Inc.. Service: 05/23/2018 by email, US mail. [524078] [17-2078] [Wenying Chang] [Entered: 05/23/2018 04:59 PM] (0) |
| May 15, 2018 | 118 | Response to oral argument order from the Appellant Acorda Therapeutics, Inc.. Designating Bruce M. Wexler, Paul Hastings LLP to argue.. Designating 15 minutes for argument. Reserving 3 minutes for rebuttal. [17-2078] [Bruce Wexler] [Entered: 05/15/2018 07:23 AM] (0) |
| May 15, 2018 | 119 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [118], ERROR: Counsel for Appellant Acorda Therapeutics, Inc. submitted a response to the oral argument order indicating 15 minutes for argument and 3 minutes for rebuttal. The Oral Argument Order issued with the Notice of Calendaring states that unless otherwise directed by the court, total argument time is 15 minutes per side. CORRECTION: Please promptly submit a corrected response. [521593] [JAB] [Entered: 05/15/2018 08:39 AM] (0) |
| May 15, 2018 | 120 | CORRECTED Response to oral argument order from the Appellant Acorda Therapeutics, Inc.. Designating Bruce M. Wexler, Paul Hastings LLP to argue.. Designating 12 minutes for argument. Reserving 3 minutes for rebuttal. [17-2078] [Bruce Wexler] [Entered: 05/15/2018 09:07 AM] (0) |
| May 15, 2018 | 121 | Response to oral argument order from the Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Designating Charles B. Klein to argue.. Designating 14 minutes for argument. Reserving 1 minutes for rebuttal. [17-2078] [Charles Klein] [Entered: 05/15/2018 10:39 AM] (0) |
| Apr 20, 2018 | 117 | NOTICE OF CALENDARING. Panel: 1806L. Case scheduled Jun 07, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to oral argument order due: 05/15/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [515701] [JAB] [Entered: 04/20/2018 02:13 PM] (0) |
| Apr 19, 2018 | 116 | ORDER filed. The motion [115] is granted to the extent that these appeals will be placed on the June 2018 oral argument calendar. Service: 04/19/2018 by clerk. [515206] [LMS] [Entered: 04/19/2018 11:27 AM] (2) |
| Apr 18, 2018 | 115 | MOTION of Appellant Acorda Therapeutics, Inc. to schedule oral argument [Consent: partial consent]. Service: 04/18/2018 by email. [515069] [17-2078] [Igor Timofeyev] [Entered: 04/18/2018 07:45 PM] (11) |
| Apr 6, 2018 | 114 | Letter from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. Corrected letter clearing the conflict for the Court's June oral argument session.. Service: 04/06/2018 by email. [511290] [17-2078] [Reid Smith] [Entered: 04/06/2018 12:36 PM] (1) |
| Mar 26, 2018 | 113 | Notice from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (June 4 - June 8, 2018; July 9 - July 13, 2018). Service: 03/26/2018 by email. [508024] [17-2078] [Reid Smith] [Entered: 03/26/2018 05:02 PM] (3) |
| Feb 27, 2018 | 110 | Amended Entry of appearance for Robert L. Florence as principal counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501500] [Robert Florence] [Entered: 02/27/2018 03:52 PM] (2) |
| Feb 27, 2018 | 111 | Amended Entry of appearance for Micheal L. Binns as of counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501507] [Micheal Binns] [Entered: 02/27/2018 03:59 PM] (2) |
| Feb 27, 2018 | 112 | Amended Entry of appearance for Karen L. Carroll as of counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501512] [Karen Carroll] [Entered: 02/27/2018 04:05 PM] (2) |
| Dec 13, 2017 | 107 | Notice from Appellant Acorda Therapeutics, Inc. regarding conflicts with oral argument (No conflicts during February, March, or April argument sessions). Service: 12/13/2017 by email. [482504] [Bruce Wexler] [Entered: 12/13/2017 05:18 PM] (2) |
| Dec 13, 2017 | 108 | Notice from Cross-Appellant Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (February 6, 2018 through February 8, 2018). Service: 12/13/2017 by email. [482517] [Robert Florence] [Entered: 12/13/2017 08:00 PM] (3) |
| Dec 13, 2017 | 109 | Notice from Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (February 5, 2018 - February 9, 2018). Service: 12/13/2017 by email. [482522] [Reid Smith] [Entered: 12/13/2017 10:30 PM] (3) |
| Dec 8, 2017 | 106 | 6 paper copies of the Joint Appendix [104] received from Appellant Acorda Therapeutics, Inc. [481696] [JCP] [Entered: 12/11/2017 04:03 PM] (0) |
| Dec 6, 2017 | 105 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [FEB, MAR, APR], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 12/13/2017. [480579] [MJL] [Entered: 12/06/2017 12:16 PM] (0) |
| Dec 5, 2017 | 103 | 6 paper copies of the Reply Brief [98] received from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [480306] [CW] [Entered: 12/05/2017 01:02 PM] (0) |
| Dec 4, 2017 | 99 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 12/04/2017 by email. [480012] [Charles Klein] [Entered: 12/04/2017 03:31 PM] (3) |
| Dec 4, 2017 | 100 | TENDERED from Amici Curiae Biotechnology Innovation Organization, Pharmaceutical Research and Manufacturers of America, Appellant Acorda Therapeutics, Inc., Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: JOINT APPENDIX. Service: 12/04/2017 by email. [480098] [Bruce Wexler] [Entered: 12/04/2017 06:03 PM] (631) |
| Dec 4, 2017 | 101 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Acorda Therapeutics, Inc., Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 12/04/2017 by email. [480115] [Bruce Wexler] [Entered: 12/04/2017 06:34 PM] (4) |
| Dec 4, 2017 | 102 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Acorda Therapeutics, Inc. and Appellee Alkermes Pharma Ireland Limited. Service: 12/04/2017 by email. [480117] [Bruce Wexler] [Entered: 12/04/2017 06:41 PM] (3) |
| Dec 4, 2017 | 104 | APPENDIX FILED for Acorda Therapeutics, Inc. [100]. Number of Pages: 631. Service: 12/04/2017 by email. The paper copies of the appendix should be received by the court on or before 12/13/2017. [480551] [MJL] [Entered: 12/06/2017 11:42 AM] (631) |
| Nov 27, 2017 | 97 | TENDERED from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: REPLY BRIEF. Service: 11/27/2017 by email. [478404] [Charles Klein] [Entered: 11/27/2017 06:12 PM] (14) |
| Nov 27, 2017 | 98 | REPLY BRIEF FILED for Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [97]. Number of Pages: 8. Service: 11/27/2017 by email. The paper copies of the brief should be received by the court on or before 12/08/2017. Appendix is due 12/07/2017. [479515] [MJL] [Entered: 12/01/2017 09:29 AM] (14) |
| Nov 22, 2017 | 96 | 6 paper copies of the Corrected Reply Brief [93] received from Appellant Acorda Therapeutics, Inc. and Appellee Alkermes Pharma Ireland Limited. [477823] [CW] [Entered: 11/22/2017 12:17 PM] (0) |
| Nov 20, 2017 | 94 | Notice of Rejection to Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc., the following document cannot be filed: party letter [89]. Reason: incorrect event.. [476871] [MJL] [Entered: 11/20/2017 09:49 AM] (1) |
| Nov 20, 2017 | 95 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 11/20/2017 by email. [476936] [Charles Klein] [Entered: 11/20/2017 11:50 AM] (20) |
| Nov 15, 2017 | 91 | Notice of Correction to the Brief Doc No. [90] for Appellant Acorda Therapeutics, Inc.. Service: 11/15/2017 by email. [475923] [Bruce Wexler] [Entered: 11/15/2017 04:08 PM] (5) |
| Nov 15, 2017 | 92 | TENDERED from Appellant Acorda Therapeutics, Inc. and Appellee Alkermes Pharma Ireland Limited. Title: CORRECTED REPLY BRIEF. Service: 11/15/2017 by email. [475927] [Bruce Wexler] [Entered: 11/15/2017 04:18 PM] (61) |
| Nov 15, 2017 | 93 | CORRECTED RESPONSE AND REPLY BRIEF FILED for Appellant Acorda Therapeutics, Inc. and Appellee Alkermes Pharma Ireland Limited [92]. Number of Pages: 51. Service: 11/15/2017 by email. The paper copies of the brief should be received by the court on or before 11/29/2017. Cross-Appellant's reply brief is due 11/27/2017. [476866] [MJL] [Entered: 11/20/2017 09:41 AM] (61) |
| Nov 13, 2017 | 89 | Letter from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. Rule 28(j). Service: 11/13/2017 by email. [474603]. This document has been rejected. See Doc. No. [94]. [Charles Klein] [Entered: 11/13/2017 08:55 AM] (0) |
| Nov 13, 2017 | 90 | TENDERED from Appellant Acorda Therapeutics, Inc.. Title: REPLY BRIEF. Service: 11/13/2017 by email. [475079]. This brief has been corrected. See Doc. No. [93]. [Bruce Wexler] [Entered: 11/13/2017 09:52 PM] (0) |
| Oct 10, 2017 | 88 | 6 paper copies of the Corrected Opening Response Brief [87] received from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [466567] [CW] [Entered: 10/10/2017 03:13 PM] (0) |
| Oct 6, 2017 | 86 | TENDERED from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: CORRECTED OPENING BRIEF. Service: 10/06/2017 by email. [466099] [Charles Klein] [Entered: 10/06/2017 01:00 PM] (83) |
| Oct 6, 2017 | 87 | CORRECTED BRIEF FILED for Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [86]. Number of Pages: 66. Service: 10/06/2017 by email. The paper copies of the brief should be received by the court on or before 10/16/2017. [466120] [MJL] [Entered: 10/06/2017 01:40 PM] (83) |
| Oct 3, 2017 | 85 | NOTICE OF REJECTION: The brief of Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [83] is not in compliance with the rules of this court and is therefore rejected for filing. Corrected brief due 10/17/2017. Appellant Acorda Therapeutics, Inc.'s response and reply brief and Appellee Alkermes Pharma Ireland Limited's response brief are due 11/13/2017. Service as of this date by Clerk of Court. [465074] [MJL] [Entered: 10/03/2017 11:54 AM] (2) |
| Oct 2, 2017 | 82 | Amended Certificate of Interest for the Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 10/02/2017 by email. [464740] [Robert Florence] [Entered: 10/02/2017 01:12 PM] (3) |
| Oct 2, 2017 | 83 | TENDERED from Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: OPENING BRIEF. Service: 10/02/2017 by email. [464905]. This brief has been rejected. See Doc. No. [85]. [Charles Klein] [Entered: 10/02/2017 05:43 PM] (0) |
| Oct 2, 2017 | 84 | Certificate of Interest for the Appellant Acorda Therapeutics, Inc.. Service: 10/02/2017 by email. [464926] [Bruce Wexler] [Entered: 10/02/2017 10:14 PM] (3) |
| Sep 28, 2017 | 80 | Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 09/28/2017 by email. [464144] [Charles Klein] [Entered: 09/28/2017 03:37 PM] (3) |
| Sep 28, 2017 | 81 | Certificate of Interest for the Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 09/28/2017 by email. [464149] [Charles Klein] [Entered: 09/28/2017 03:40 PM] (3) |
| Aug 30, 2017 | 79 | ORDER filed. The motion [78] is granted. Service: 08/30/2017 by clerk. [457780] [LMS] [Entered: 08/30/2017 02:56 PM] (2) |
| Aug 25, 2017 | 78 | MOTION of Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to extend the time to 10/02/2017 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 08/25/2017 by email. [456881] [Charles Klein] [Entered: 08/25/2017 04:50 PM] (8) |
| Aug 18, 2017 | 77 | 6 paper copies of the Amicus Brief [73] received from Amicus Curiae Biotechnology Innovation Organization. [455120] [CW] [Entered: 08/18/2017 01:15 PM] (0) |
| Aug 17, 2017 | 75 | Certificate of Interest for the Amicus Curiae Biotechnology Innovation Organization. Service: 08/17/2017 by email. [454622] [Sarah Kagan] [Entered: 08/17/2017 08:45 AM] (2) |
| Aug 17, 2017 | 76 | 6 paper copies of the Amicus Brief [74] received from Amicus Curiae Pharmaceutical Research and Manufacturers of America. [454742] [CW] [Entered: 08/17/2017 12:23 PM] (0) |
| Aug 14, 2017 | 63 | Entry of appearance for Sarah A. Kagan as principal counsel for BIOTECHNOLOGY INNOVATION ORGANIZATION. Service: 08/14/2017 by email. [453791] [Sarah Kagan] [Entered: 08/14/2017 03:26 PM] (2) |
| Aug 14, 2017 | 64 | Entry of appearance for Melissa Brand as of counsel for BIOTECHNOLOGY INNOVATION ORGANIZATION. Service: 08/14/2017 by email. [453792] [Sarah Kagan] [Entered: 08/14/2017 03:27 PM] (2) |
| Aug 14, 2017 | 65 | Entry of appearance for Lisa M. Hemmendinger as of counsel for BIOTECHNOLOGY INNOVATION ORGANIZATION. Service: 08/14/2017 by email. [453793] [Sarah Kagan] [Entered: 08/14/2017 03:28 PM] (2) |
| Aug 14, 2017 | 66 | Entry of appearance for Hansjorg Sauer as of counsel for BIOTECHNOLOGY INNOVATION ORGANIZATION. Service: 08/14/2017 by email. [453796] [Sarah Kagan] [Entered: 08/14/2017 03:29 PM] (2) |
| Aug 14, 2017 | 67 | TENDERED from BIOTECHNOLOGY INNOVATION ORGANIZATION Title: AMICUS CURIAE BRIEF. Service: 08/14/2017 by email. [453797] [Sarah Kagan] [Entered: 08/14/2017 03:30 PM] (31) |
| Aug 14, 2017 | 68 | Entry of appearance for Scott E. Kamholz as principal counsel for Pharmaceutical Research and Manufacturers of America. Service: 08/14/2017 by email. [453864] [Scott Kamholz] [Entered: 08/14/2017 05:20 PM] (2) |
| Aug 14, 2017 | 69 | Entry of appearance for David E. Korn as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 08/14/2017 by email. [453867] [Scott Kamholz] [Entered: 08/14/2017 05:23 PM] (2) |
| Aug 14, 2017 | 70 | Entry of appearance for Brianne Bharkhda as of counsel for Pharmaceutical Research and Manufacturers of America. Service: 08/14/2017 by email. [453869] [Brianne Bharkhda] [Entered: 08/14/2017 05:30 PM] (2) |
| Aug 14, 2017 | 71 | Certificate of Interest for Pharmaceutical Research and Manufacturers of America. Service: 08/14/2017 by email. [453871] --[Edited 08/15/2017 by clerk to correct party filer] [Scott Kamholz] [Entered: 08/14/2017 05:38 PM] (2) |
| Aug 14, 2017 | 72 | TENDERED from Pharmaceutical Research and Manufacturers of America Title: AMICUS CURIAE BRIEF. Service: 08/14/2017 by email. [453872] [Scott Kamholz] [Entered: 08/14/2017 05:43 PM] (27) |
| Aug 14, 2017 | 73 | AMICUS BRIEF FILED for Biotechnology Innovation Organization [67]. Number of Pages: 22. Service: 08/14/2017 by email. The paper copies of the brief should be received by the court on or before 08/23/2017. The certificate of interest must be filed as a separate docket entry promptly. [454253] [MJL] [Entered: 08/16/2017 09:20 AM] (31) |
| Aug 14, 2017 | 74 | AMICUS BRIEF FILED for Pharmaceutical Research and Manufacturers of America [72]. Number of Pages: 19. Service: 08/14/2017 by email. The paper copies of the brief should be received by the court on or before 08/23/2017. [454254] [MJL] [Entered: 08/16/2017 09:21 AM] (27) |
| Aug 11, 2017 | 59 | REMINDER: All counsel of record are reminded of their responsibility per FCR 47.3(c)(1) and 47.4(b) to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [453294] [MJL] [Entered: 08/11/2017 11:22 AM] (0) |
| Aug 11, 2017 | 60 | 6 paper copies of the Corrected Opening Brief [58] received from Appellant Acorda Therapeutics, Inc. [453309] [CW] [Entered: 08/11/2017 11:39 AM] (0) |
| Aug 11, 2017 | 61 | Amended Entry of appearance for Garrard R. Beeney as of counsel for Appellant Acorda Therapeutics Inc.. Service: 08/11/2017 by email. [453507]--[Edited 08/14/2017 by clerk to correct docket text] [Garrard Beeney] [Entered: 08/11/2017 04:51 PM] (1) |
| Aug 11, 2017 | 62 | Amended Entry of appearance for Bruce M. Wexler as principal counsel for Appellant Acorda Therapeutics, Inc.. Service: 08/11/2017 by email. [453528] [Bruce Wexler] [Entered: 08/11/2017 07:08 PM] (2) |
| Aug 9, 2017 | 56 | Notice of Correction to the Brief Doc No. [55]. Service: 08/09/2017 by email. [452770] [Bruce Wexler] [Entered: 08/09/2017 04:01 PM] (5) |
| Aug 9, 2017 | 57 | TENDERED from Appellant Acorda Therapeutics, Inc.. Title: CORRECTED OPENING BRIEF. Service: 08/09/2017 by email. [452771] [Bruce Wexler] [Entered: 08/09/2017 04:05 PM] (317) |
| Aug 9, 2017 | 58 | CORRECTED BRIEF FILED for Appellant Acorda Therapeutics, Inc. [57]. Number of Pages: 64. Service: 08/09/2017 by email. The paper copies of the brief should be received by the court on or before 08/16/2017. Cross-Appellants' principal and response brief(s) due 09/18/2017. [452792] [MJL] [Entered: 08/09/2017 04:28 PM] (317) |
| Aug 7, 2017 | 54 | Letter from Appellant Acorda Therapeutics, Inc. Designation of Principal Attorney of Record. Service: 08/07/2017 by email. [451934] [Bruce Wexler] [Entered: 08/07/2017 10:56 PM] (2) |
| Aug 7, 2017 | 55 | TENDERED from Appellant Acorda Therapeutics, Inc.. Title: OPENING BRIEF. Service: 08/07/2017 by email. [451935]. This brief has been corrected. See Doc. No. [58]. [Bruce Wexler] [Entered: 08/07/2017 10:59 PM] (0) |
| Jul 17, 2017 | 52 | MOTION of Appellant Acorda Therapeutics, Inc., Appellee Alkermes Pharma Ireland Limited and Cross-Appellants Mylan Pharmaceuticals Inc., Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. to extend the time to 08/07/2017 at 11:59 pm to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 07/17/2017 by email. [446760] [Bruce Wexler] [Entered: 07/17/2017 07:41 AM] (12) |
| Jul 17, 2017 | 53 | ORDER granting motion to extend time to file Appellant's principal brief [52] filed by Appellant Acorda Therapeutics, Inc., Cross-Appellants Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Roxane Laboratories, Inc., and Appellee Alkermes Pharma Ireland Limited. Appellant's brief is due 8/7/2017. Service as of this date by Clerk of Court. [446979] [ABY] [Entered: 07/17/2017 01:10 PM] (3) |
| Jul 5, 2017 | 51 | ORDER filed. Acorda Therapeutics, Inc.’s opening brief is due no later than July 24, 2017. No later than 40 days thereafter, the cross-appellants’ opening and response briefs are due. No later than 40 days thereafter, Acorda’s response and reply brief and Alkermes Pharma Ireland Limited’s response brief are due. No later than 14 days thereafter, the cross-appellants’ reply briefs are due. The joint appendix is due no later than 10 days thereafter. Service: 07/05/2017 by clerk. [444216] [LMS] [Entered: 07/05/2017 02:30 PM] (2) |
| Jun 30, 2017 | 50 | Entry of appearance for Karen L. Carroll as of counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/30/2017 by email. [443360] [Karen Carroll] [Entered: 06/30/2017 10:04 AM] (2) |
| Jun 22, 2017 | 48 | Entry of appearance for Bryce A. Cooper as of counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/22/2017 by email. [441495] [Bryce Cooper] [Entered: 06/22/2017 03:57 PM] (2) |
| Jun 22, 2017 | 49 | Entry of appearance for Reid F. Smith as of counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/22/2017 by email. [441499] [Reid Smith] [Entered: 06/22/2017 04:03 PM] (2) |
| Jun 15, 2017 | 47 | Entry of appearance for Micheal L. Binns as of counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/15/2017 by email. [439669] [Micheal Binns] [Entered: 06/15/2017 02:34 PM] (2) |
| Jun 14, 2017 | 43 | Entry of appearance for Maryellen Noreika as principal counsel for Appellee Alkermes Pharma Ireland Limited. Service: 06/14/2017 by email. [439167] [Maryellen Noreika] [Entered: 06/14/2017 12:07 PM] (2) |
| Jun 14, 2017 | 44 | Entry of appearance for Jeremy A. Tigan as of counsel for Appellee Alkermes Pharma Ireland Limited. Service: 06/14/2017 by email. [439168] [Maryellen Noreika] [Entered: 06/14/2017 12:08 PM] (2) |
| Jun 14, 2017 | 45 | Docketing Statement for the Appellee Alkermes Pharma Ireland Limited. Service: 06/14/2017 by email. [439170] [Maryellen Noreika] [Entered: 06/14/2017 12:09 PM] (3) |
| Jun 14, 2017 | 46 | Certificate of Interest for the Appellee Alkermes Pharma Ireland Limited. Service: 06/14/2017 by email. [439173] [Maryellen Noreika] [Entered: 06/14/2017 12:10 PM] (2) |
| Jun 12, 2017 | 42 | Corrected Docketing Statement for the Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/12/2017 by email. [438503] [Robert Florence] [Entered: 06/12/2017 04:11 PM] (3) |
| Jun 8, 2017 | 34 | NOTICE OF DEFICIENCY: The entries of appearance for Charles B. Klein [23], George C. Lombardi [24], Andrew C. Nichols [25], and Samuel S. Park [26] and docketing statements for Teva Pharmaceuticals USA, Inc. [29] and Roxane Laboratories, Inc. [33] cannot be accepted for filing at this time (see attached document). You are being afforded the opportunity to correct the deficiencies. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [437428] [MJL] [Entered: 06/08/2017 10:07 AM] (1) |
| Jun 8, 2017 | 35 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The contact information included on the entry of appearance for Robert L. Florence [30] does not match the information in the attorney's user account. CORRECTION: Please update as needed to ensure the contact information on the entry of appearance and in the user account matches. [437435] [MJL] [Entered: 06/08/2017 10:32 AM] (0) |
| Jun 8, 2017 | 36 | Corrected Entry of appearance for Charles B. Klein as principal counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/08/2017 by email. [437599] [Charles Klein] [Entered: 06/08/2017 03:13 PM] (2) |
| Jun 8, 2017 | 37 | Corrected Entry of appearance for George C. Lombardi as of counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/08/2017 by email. [437602] [Charles Klein] [Entered: 06/08/2017 03:17 PM] (2) |
| Jun 8, 2017 | 38 | Corrected Entry of appearance for Andrew C. Nichols as of counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/08/2017 by email. [437610] [Charles Klein] [Entered: 06/08/2017 03:26 PM] (2) |
| Jun 8, 2017 | 39 | Corrected Entry of appearance for Samuel S. Park as of counsel for Cross-Appellants Roxane Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 06/08/2017 by email. [437615] [Charles Klein] [Entered: 06/08/2017 03:29 PM] (2) |
| Jun 8, 2017 | 40 | Corrected Docketing Statement for the Cross-Appellant Roxane Laboratories, Inc.. Service: 06/08/2017 by email. [437618] [Charles Klein] [Entered: 06/08/2017 03:33 PM] (3) |
| Jun 8, 2017 | 41 | Corrected Docketing Statement for the Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 06/08/2017 by email. [437620] [Charles Klein] [Entered: 06/08/2017 03:36 PM] (3) |
| Jun 7, 2017 | 20 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The contact information included on the entry of appearance for Bruce M. Wexler [17] does not match the information in the attorney's user account. CORRECTION: Please update as needed to ensure the contact information on the entry of appearance and in the user account matches. [436987] [MJL] [Entered: 06/07/2017 10:16 AM] (0) |
| Jun 7, 2017 | 21 | Note to file: The following cases are consolidated: 17-2078 (Lead) with 17-2134 (Cross-Appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [437158] [17-2078, 17-2134] [MJL] [Entered: 06/07/2017 02:01 PM] (0) |
| Jun 7, 2017 | 22 | Official caption revised to reflect cross-appeal and correct party names. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Case opening documents (EOA, COI, and Docketing Statement) for Alkermes Pharma Ireland Limited are due 06/21/2017. Service as of this date by Clerk of Court. [437161] [MJL] [Entered: 06/07/2017 02:07 PM] (0) |
| Jun 7, 2017 | 23 | Entry of appearance for Charles B. Klein as principal counsel for Appellees Roxane Laboratories Inc. and Teva Pharmaceuticals USA Inc. Service: 06/07/2017 by email, US mail. [437196] [Charles Klein] [Entered: 06/07/2017 02:55 PM] (0) |
| Jun 7, 2017 | 24 | Entry of appearance for George C. Lombardi as of counsel for Appellees Roxane Laboratories Inc. and Teva Pharmaceuticals USA Inc. Service: 06/07/2017 by email, US mail. [437203] [Charles Klein] [Entered: 06/07/2017 03:03 PM] (0) |
| Jun 7, 2017 | 25 | Entry of appearance for Andrew C. Nichols as of counsel for Appellees Roxane Laboratories Inc. and Teva Pharmaceuticals USA Inc. Service: 06/07/2017 by email, US mail. [437208] [Charles Klein] [Entered: 06/07/2017 03:06 PM] (0) |
| Jun 7, 2017 | 26 | Entry of appearance for Samuel S. Park as of counsel for Appellees Roxane Laboratories Inc. and Teva Pharmaceuticals USA Inc. Service: 06/07/2017 by email, US mail. [437211] [Charles Klein] [Entered: 06/07/2017 03:08 PM] (0) |
| Jun 7, 2017 | 27 | Certificate of Interest for the Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 06/07/2017 by email, US mail. [437220] [Charles Klein] [Entered: 06/07/2017 03:16 PM] (4) |
| Jun 7, 2017 | 28 | Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 06/07/2017 by email, US mail. [437228] [Charles Klein] [Entered: 06/07/2017 03:20 PM] (4) |
| Jun 7, 2017 | 29 | Docketing Statement for the Cross-Appellant Teva Pharmaceuticals USA, Inc.. Service: 06/07/2017 by email, US mail. [437240] [Charles Klein] [Entered: 06/07/2017 03:37 PM] (0) |
| Jun 7, 2017 | 30 | Entry of appearance for Robert L. Florence as principal counsel for Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/07/2017 by email. [437242] [Robert Florence] [Entered: 06/07/2017 03:37 PM] (2) |
| Jun 7, 2017 | 31 | Docketing Statement for the Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/07/2017 by email. [437244] [Robert Florence] [Entered: 06/07/2017 03:40 PM] (3) |
| Jun 7, 2017 | 32 | Certificate of Interest for the Cross-Appellant Mylan Pharmaceuticals Inc.. Service: 06/07/2017 by email. [437246] [Robert Florence] [Entered: 06/07/2017 03:42 PM] (2) |
| Jun 7, 2017 | 33 | Docketing Statement for the Cross-Appellant Roxane Laboratories, Inc.. Service: 06/07/2017 by email, US mail. [437247] [Charles Klein] [Entered: 06/07/2017 03:42 PM] (0) |
| Jun 6, 2017 | 15 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Stephen J. Elliott (EOA [5]) is not a registered CM/ECF filer with the Federal Circuit. CORRECTION: Pursuant to FCR 25(a)(2), attorneys who appear before this court must register for the court's CM/ECF system. Please register promptly. [436784] [MJL] [Entered: 06/06/2017 02:56 PM] (0) |
| Jun 6, 2017 | 16 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The contact information included on the entries of appearance for Alexandra H. Moss [6] and Gerald J. Flattmann [12] does not match the information in the attorneys' user accounts. CORRECTION: Please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. [436785] [MJL] [Entered: 06/06/2017 02:58 PM] (0) |
| Jun 6, 2017 | 17 | Amended Entry of appearance for Bruce M. Wexler as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/06/2017 by email, US mail. [436884] [Bruce Wexler] [Entered: 06/06/2017 05:24 PM] (2) |
| Jun 6, 2017 | 18 | Amended Entry of appearance for Gerald J. Flattmann as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/06/2017 by email, US mail. [436886] [Gerald Flattmann] [Entered: 06/06/2017 05:28 PM] (2) |
| Jun 6, 2017 | 19 | Objection to the official caption pursuant to Rule 12 Practice Note by Appellant Acorda Therapeutics Inc.. Service: 06/06/2017 by email, US mail. [436915] [Alexandra Moss] [Entered: 06/06/2017 10:21 PM] (3) |
| Jun 5, 2017 | 2 | Entry of appearance for Garrard R. Beeney as principal counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436469] [Garrard Beeney] [Entered: 06/05/2017 04:31 PM] (2) |
| Jun 5, 2017 | 3 | Docketing Statement for the Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436475] [Garrard Beeney] [Entered: 06/05/2017 04:36 PM] (3) |
| Jun 5, 2017 | 4 | Certificate of Interest for the Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436476] [Garrard Beeney] [Entered: 06/05/2017 04:38 PM] (2) |
| Jun 5, 2017 | 5 | Entry of appearance for Stephen J. Eliott as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436478] [Garrard Beeney] [Entered: 06/05/2017 04:45 PM] (2) |
| Jun 5, 2017 | 6 | Entry of appearance for Alexandra H. Moss as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436481] [Garrard Beeney] [Entered: 06/05/2017 04:50 PM] (2) |
| Jun 5, 2017 | 7 | Entry of appearance for Wen-Ying Angela Chang as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436483] [Garrard Beeney] [Entered: 06/05/2017 04:54 PM] (2) |
| Jun 5, 2017 | 8 | Entry of appearance for Jane Wasman as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436486] [Garrard Beeney] [Entered: 06/05/2017 04:57 PM] (2) |
| Jun 5, 2017 | 9 | Entry of appearance for Anthony Michael as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436490] [Garrard Beeney] [Entered: 06/05/2017 04:59 PM] (2) |
| Jun 5, 2017 | 10 | Letter from Appellant Acorda Therapeutics Inc. Correction of Case Caption. Service: 06/05/2017 by email. [436491] [Garrard Beeney] [Entered: 06/05/2017 05:03 PM] (2) |
| Jun 5, 2017 | 11 | Entry of appearance for Bruce M. Wexler as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436507] [Bruce Wexler] [Entered: 06/05/2017 07:25 PM] (2) |
| Jun 5, 2017 | 12 | Entry of appearance for Gerald J. Flattmann as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436508] [Gerald Flattmann] [Entered: 06/05/2017 07:29 PM] (2) |
| Jun 5, 2017 | 13 | Entry of appearance for Stephen B. Kinnaird as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436509] [Stephen Kinnaird] [Entered: 06/05/2017 07:34 PM] (2) |
| Jun 5, 2017 | 14 | Entry of appearance for Igor V. Timofeyev as of counsel for Appellant Acorda Therapeutics Inc.. Service: 06/05/2017 by email. [436510] [Igor Timofeyev] [Entered: 06/05/2017 07:36 PM] (2) |
| May 24, 2017 | 1 | Appeal docketed. Received: 05/23/2017. [433866]Entry of Appearance due 06/07/2017. Certificate of Interest due 06/07/2017. Docketing Statement due 06/07/2017. Appellant's brief due 07/24/2017. [MJL] [Entered: 05/24/2017 02:44 PM] (135) |
